A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown <i>BRCA</i> Mutation Status.

Clin Med Insights Oncol · 2018 · PMC6104219 · PMID 30150877

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

did not reach statistical significanceP = .07so close (0.05 < p ≤ 0.1)

In the CisCT group, there were more patients with stage II/III disease (80%) than in the noCisCT group (59%), although this did not reach statistical significance ( P = .07 using Fisher exact test).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.